Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2010, Vol. 4 Issue (1) : 90-95     DOI: 10.1007/s11684-010-0021-x
Research articles |
Cyclooxygenase-2 gene-1195G/A genotype is associated with the risk of HBV-induced HCC: A case-control study in Han Chinese people
Li-Feng LIU MD, PhD1,Qiong CHEN MD, PhD1,Ying CHANG MD, PhD1,Ju-Sheng LIN MD, PhD1,Jin-Liang ZHANG MM2,
1.Institute of Liver Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 2.Department of Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China;
Download: PDF(190 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  This study aimed to identify functional single nucleotide polymorphisms in the cyclooxygenase-2 gene promoter and evaluate their effects on the risk of primary hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) infection. We conducted a population-based, case-control study enrolling 630 Han Chinese people in Hubei province. Subjects included primary HCC patients with HBV infection (n=210), chronic hepatitis B cases (n=210) and healthy Han Chinese (n=210). -1195G/A polymorphism was analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and sequencing analysis. We found-1195A allele carriers had a higher risk of HCC with HBV infection (OR, 0.72; 95% CI, 0.548–0.946). The-1195A allele might be used as a marker in screening individuals at high risk of HCC with HBV infection.
Keywords cyclooxygenase-2 gene      single nucleotide polymorphisms      susceptibility      primary hepatocellular carcinoma      hepatitis B virus infection      
Issue Date: 05 March 2010
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-010-0021-x     OR     http://academic.hep.com.cn/fmd/EN/Y2010/V4/I1/90
Needleman P, Turk J, Jakschik B A, Morrison A R, Lefkowith J B. Arachidonic acid metabolism. Annu RevBiochem, 1986, 55: 69―102

doi: 10.1146/annurev.bi.55.070186.000441
Williams C S, Mann M, DuBois R N. The role of cyclooxygenases in inflammation,cancer, and development. Oncogene, 1999, 18: 7908―7916

doi: 10.1038/sj.onc.1203286
Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasias. Ann Clin Lab Sci, 2000, 30: 3―21
Trifan O C, Hla T. Cyclooxygenase-2modulates cellular growth and promotes tumorigenesis. Cell Mol Med, 2003, 7(3): 207―222

doi: 10.1111/j.1582-4934.2003.tb00222.x
Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev, 2000, 19(1―2): 19―27

doi: 10.1023/A:1026575610124
Vane J R, Bakhle Y S, Botting R M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol, 1998, 38: 97―120

doi: 10.1146/annurev.pharmtox.38.1.97
Smith W L, Garavito R M, DeWitt D L. Prostaglandin endoperoxideH synthases (cyclooxygenases)-1 and-2. J Biol Chem, 1996, 271(52): 33157―33160

doi: 10.1074/jbc.271.52.33157
Taketo M M. COX-2 and colon cancer. InflammRes, 1998, 47 (Suppl 2): S112―S116

doi: 10.1007/s000110050295
Ding X Z, Tong W G, Adrian T E. Blockade of cyclooxygenase-2 inhibitsproliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res, 2000, 20(4): 2625―2631
Li M, Wu X, Xu X C. Induction of apoptosis in colon cancercells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependentpathway. Clin Cancer Res, 2001, 7(4): 1010―1016
Sheng H, Shao J, Washington M K, DuBois R N. Prostaglandin E2 increases growth and motility of colorectalcarcinoma cells. J Biol Chem, 2001, 276(21): 18075―18081

doi: 10.1074/jbc.M009689200
Chen W S, Wei S J, Liu J M, Hsiao M, Kou-Lin J, Yang W K. Tumor invasiveness and liver metastasis of colon cancercells correlated with cyclooxygenase-2 (COX-2) expression and inhibitedby a COX-2-selective inhibitor, etodolac. Int J Cancer, 2001, 91(6): 894―899

doi: 10.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.0.CO;2-#
Masferrer J L, Leahy K M, Koki A T, Zweifel B S, Settle S L, Woerner B M, Edwards D A, Flickinger A G, Moore R J, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res, 2000, 60(5): 1306―1311
Eberhart C E, Coffey R J, Radhika A, Giardiello F M, Ferrenbach S, DuBois R N. Up-regulation of cyclooxygenase 2 gene expression inhuman colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107(4): 1183―1188
Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimäki A. Expression of cyclooxygenase-2in human lung carcinoma. Cancer Res, 1998, 58(22): 4997―5001
Chan G, Boyle J O, Yang E K, Zhang F, Sacks P G, Shah J P, Edelstein D, Soslow R A, Koki A T, Woerner B M, Masferrer J L, Dannenberg A J. Cyclooxygenase-2 expression is up-regulated in squamouscell carcinoma of the head and neck. CancerRes, 1999, 59(5): 991―994
Ratnasinghe D, Tangrea J, Roth M J, Dawsey S, Hu N, Anver M, Wang Q H, Taylor P R. Expression of cyclooxygenase-2in human squamous cell carcinoma of the esophagus; an immunohistochemicalsurvey. Anticancer Res, 1999, 19(1A): 171―174
Fujita H, Koshida K, Keller E T, Takahashi Y, Yoshimito T, Namiki M, Mizokami A. Cyclooxygenase-2 promotes prostate cancer progression. Prostrate, 2002, 53(3): 232―240

doi: 10.1002/pros.10152
Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett, 2003, 191(2): 125―135

doi: 10.1016/S0304-3835(02)00524-4
Gupta S, Srivastava M, Ahmad N, Bostwick D G, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate, 2000, 42(1): 73―78

doi: 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G
Chi-Man Tang T, Tung-Ping Poon R, Fan S T. The significance of cyclooxygenase-2expression in human hepatocellular carcinoma. Biomedicine & Pharmacotherapy, 2005, 59 Suppl 2: S311―S316

doi: 10.1016/S0753-3322(05)80053-8
Lu W, Dong J, Huang Z, Guo D, Liu Y, Shi S. Comparison of four current staging systems for Chinesepatients with hepatocellular carcinoma undergoing curative resection:Okuda, CLIP, TNM and CUPI. J Gastroen Hepatol, 2008, 2(12): 1874―1878

doi: 10.1111/j.1440-1746.2008.05527.x
Thorgeirsson S S, Grisham J W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet, 2002, 31(4): 339―346

doi: 10.1038/ng0802-339
Buendia M A. Genetics of hepatocellular carcinoma. Semin Cancer Biol, 2000, 10(3): 185―200

doi: 10.1006/scbi.2000.0319
Cox D G, Pontes C, Guino E. Polymorphisms in prostaglandin synthase2/cyclooxygen2 (PTGS2/COX-2) and risk of colorectal cancer. Br J Cancer, 2004, 91(2): 339―343
Li M, Wu X, Xu X C. Induction of apoptosis in colon cancercells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependentpathway. Clin Cancer Res, 2001, 7(4): 1010―1016
Sheng H, Shao J, Washington M K, DuBois R N. Prostaglandin E2 increases growth and motility of colorectalcarcinoma cells. J Biol Chem, 2001, 276(21): 8075―8081

doi: 10.1074/jbc.M009689200
Chen W S, Wei S J, Liu J M, Hsiao M, Kou-Lin J, Yang W K. Tumor invasiveness and liver metastasis of colon cancercells correlated with cyclooxygenase-2 (COX-2) expression and inhibitedby a COX-2-selective inhibitor, etodolac. Int J Cancer, 2001, 91(6): 894―899

doi: 10.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.0.CO;2-#
Eberhart C E, Coffey R J, Radhika A, Giardiello F M, Ferrenbach S, DuBois R N. Up-regulation of cyclooxygenase 2 gene expression inhuman colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107(4): 1183―1188
Hu Z, Miao X, Ma H, Wang X, Tan W, Wei Q, Lin D, Shen H. Common polymorphism in the 3’ UTRof cyclooxygenase 2 / prostaglandin synthase 2 gene and risk of lungcancerin a Chinese population. Lung Cancer, 2005, 48(1): 11―17

doi: 10.1016/j.lungcan.2004.09.004
Chan G, Boyle J O, Yang E K, Zhang F, Sacks P G, Shah J P, Edelstein D, Soslow R A, Koki A T, Woerner B M, Masferrer J L, Dannenberg A J. Cyclooxygenase-2 expression is up-regulated in squamouscell carcinoma of the head and neck. CancerRes, 1999, 59(5): 991―994
Ratnasinghe D, Tangrea J, Roth M J, Dawsey S, Hu N, Anver M, Wang Q H, Taylor P R. Expression of cyclooxygenase-2in human squamous cell carcinoma of the esophagus; an immunhistochemicalsurvey. Anticancer Res, 1999, 19(1A): 171―174
Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y, Song W, Guo Y, Zhang X, Shen Y, Qiang B, Kadlubar F F, Lin D. Identification of functionalgenetic variants in cyclooxygenase-2 and their association with riskof esophageal cancer. Gastroenterology, 2005, 129(2): 565―576
Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, Matsuura N, Wakasa K, Nakamori S, Sakon M, Monden M. Increased expression of COX-2 in nontumor liver tissueis associated with shorter disease-free survival in patients withhepatocellular carcinoma. Clin Cancer Res, 1999, 5(12): 4005―4012
Morinaga S, Yamamoto Y, Noguchi Y, Imada T, Rino Y, Akaike M, Sugimasa Y, Takemiya S, Kameda Y, Takanashi Y. Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitisliver adjacent to hepatocellular carcinoma. J Gastroenterol Hepatol, 2002, 17(10): 1110―1116

doi: 10.1046/j.1440-1746.2002.02836.x
Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, Kojiro M, Kurohiji T, Sata M. Expression of cyclooxygenase-2in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology, 1999, 29(3): 688―696

doi: 10.1002/hep.510290355
Casado M, Callejas N A, Rodrigo J, Zhao X, Dey S K, Bosca L, Martin-Sanz P. Contributionof cyclooxygenase 2 to liver regeneration after partial hepatectomy. FASEB J, 2001, 15(11): 2016―2018
Yamamoto H, Kondo M, Nakamori S, Nagano H, Wakasa K, Sugita Y, Chang-De J, Kobayashi S, Damdinsuren B, Dono K, Umeshita K, Sekimoto M, Sakon M, Matsuura N, Monden M. JTE-522, acyclooxygenase-2 inhibitor, is an effective chemopreventive agentagainst rat experimental liver fibrosis1. Gastroenterology, 2003, 125(2): 556―571

doi: 10.1016/S0016-5085(03)00904-1
Reilly T P, Brady J N, Marchick M R, Bourdi M, George J W, Radonovich M F, Pise-Masison C A, Pohl L R. A protective role for cyclooxygenase-2 in drug-induced liver injuryin mice. Chem Res Toxicol, 2001, 14(12): 1620―1628

doi: 10.1021/tx0155505
Abiru S, Nakao K, Ichikawa T, Migita K, Shigeno M, Sakamoto M, Ishikawa H, Hamasaki K, Nakata K, Eguchi K. Aspirin andNS-398 inhibit hepatocyte growth factor-induced invasiveness of humanhepatoma cells. Hepatology, 2002, 35(5): 1117―1124

doi: 10.1053/jhep.2002.32676
Kern M A, Schubert D, Sahi D, Schoneweiss M M, Moll I, Haugg A M, Dienes H P, Breuhahn K, Schirmacher P. Proapoptotic and antiproliferativepotential of selective cyclooxygenase-2 inhibitors in human livertumor cells. Hepatology, 2002, 36(4 Pt 1): 885―894
Kondo M, Yamamoto H, Nagano H, Okami J, Ito Y, Shimizu J, Eguchi H, Miyamoto A, Dono K, Umeshita K, Matsuura N, Wakasa K, Nakamori S, Sakon M, Monden M. Increased expression of COX-2 in nontumor liver tissueis associated with shorter disease-free survival in patients withhepatocellular carcinoma. Clin Cancer Res, 1999, 5(12): 4005―4012
Nunez O, Fernandez-Martinez A, Majano P L, Apolinario A, Gomez-Gonzalo M, Benedicto I, Lopez-Cabrera M, Bosca L, Clemente G, Garcia-Monzon C, Martin-Sanz P. Increased intrahepatic cyclooxygenase-2, matrix metalloproteinase-2,and matrix metalloproteinase-9 expression is associated with progressiveliver disease in chronic hepatitis C virus infection: role of viralcore and NS5A proteins. Gut, 2004, 53(11): 1665―1672

doi: 10.1136/gut.2003.038364
Panguluri R C, Long L O, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles R A. COX-2 gene promoter haplotypesand prostate cancer risk. Carcinogenesis, 2004, 25(6): 961―966

doi: 10.1093/carcin/bgh100
Gao J, Ke Q, Ma H X, Wang Y, Zhou Y, Hu Z B, Zhai X J, Wang X C, Qing J W, Chen W S, Jin G F, Liu J Y, Tan Y F, Wang X R, Shen H B. Functional polymorphism inthe cyclooxygenase 2 (COX-2) gene and risk of breast cancer in a Chinesepopulation. J Toxicol Environ Health A, 2007, 70(11): 908―915

doi: 10.1080/15287390701289966
Tazawa R, Xu X M, Wu K K. Characterization of the genomic structure,chromosomal location and promoter of human prostaglandin H synthase-2gene. Biochem Biophys Res Commun, 1994, 203(1): 190―199

doi: 10.1006/bbrc.1994.2167
Liu F, Pan K, Zhang X, Zhang Y, Zhang L, Ma J, Dong C, Shen L, Li J, Deng D, Lin D, You W. Genetic variantsin cyclooxygenase-2: Expression and risk of gastric cancer and itsprecursors in a Chinese population. Gastroenterology, 2006, 130(7): 1975―1984

doi: 10.1053/j.gastro.2006.03.021
Vogel U, Christensen J, Wallin H, Friis S, Nex BA, Tjønneland A. Polymorphisms in COX-2, NSAIDuse and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res, 2007, 617(1,2): 138―146
[1] Jiangbo Du,Wenjie Xue,Yong Ji,Xun Zhu,Yayun Gu,Meng Zhu,Cheng Wang,Yong Gao,Juncheng Dai,Hongxia Ma,Yue Jiang,Jiaping Chen,Zhibin Hu,Guangfu Jin,Hongbing Shen. U-shaped association between telomere length and esophageal squamous cell carcinoma risk: a case-control study in Chinese population[J]. Front. Med., 2015, 9(4): 478-486.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed